Gyre Logo.png
Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024 16:05 ET | Gyre Therapeutics, Inc.
Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Gyre Logo.png
Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
August 13, 2024 06:00 ET | Gyre Therapeutics, Inc.
Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
Gyre Logo.png
Gyre Therapeutics to Present at Sidoti Virtual Investor Conference
August 09, 2024 07:00 ET | Gyre Therapeutics, Inc.
Gyre Therapeutics to Present at Sidoti Virtual Investor Conference
Gyre Logo.png
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
August 08, 2024 16:05 ET | Gyre Therapeutics, Inc.
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
Gyre Logo.png
Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology
June 18, 2024 16:05 ET | Gyre Therapeutics, Inc.
Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology
Gyre Logo.png
Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024 16:10 ET | Gyre Therapeutics, Inc.
Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Organovo Logo (2 Color Med-Res-082117).png
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
April 15, 2024 08:05 ET | Organovo, Inc.
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Conte
Gyre Logo.png
Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
March 26, 2024 06:00 ET | Gyre Therapeutics, Inc.
Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
logo Anervea.png
A Groundbreaking Milestone in the Treatment of NASH and Liver Fibrosis - Anervea
March 17, 2024 09:19 ET | ANERVEA DATA LABS PRIVATE LIMITED
Pune, March 17, 2024 (GLOBE NEWSWIRE) -- The recent FDA approval of Resmetirom, developed by Madrigal Pharmaceuticals, has sent ripples of excitement throughout the medical community, marking a...
Organovo Logo (2 Color Med-Res-082117).png
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
December 06, 2023 08:05 ET | Organovo, Inc.
SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and...